| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00438204 Details | 2021-04-13 Interventional | 2 | 39 | Bevacizumab Gemcitabine Pemetrexed Carcinoma, Non-… Lung Neoplasms Lung Cancer | All data collection has completed. There were no significant limitations of the trial. | |||
| NCT03906916 Details | 2021-04-12 Interventional | 4 | 14 | Micafungin Candidiasis Candidiasis, In… Invasive Candid… | The study was interrupted prematurely because of the low rate of recruitment. - | |||
| NCT03415581 Details | 2021-04-12 Interventional | 2 | 13 | Oxycodone Opioid-Related … Opioid-use Diso… | Study terminated by sponsor due to bad risk/benefit ratio. - | |||
| NCT03094611 Details | 2021-04-12 Interventional | 2 | 4 | Inotuzumab Ozog… Leukemia Leukemia, Lymph… Precursor Cell … CD22 Positive Recurrent Acute… Refractory Acut… | the study was closed early due to competing trials - | |||
| NCT02485990 Details | 2021-04-12 Interventional | 1 | 24 | Olaparib Tremelimumab Carcinoma Primary Periton… | Withdrawal of sponsor support - | |||
| NCT04839237 Details | 2021-04-09 Interventional | 2 | 0 | Liraglutide Metformin Obesity | The sponsor decides withdrawn this study. - | |||
| NCT03615924 Details | 2021-04-09 Interventional | 3 | 193 | Ticagrelor Anemia, Sickle … Sickle Cell Dis… | Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca. AstraZeneca took the decision to terminate the study early, following a recommendation from the independent Data Monitoring Committee. This early termination was not considered to have had an impact on the robustness of the study results. | |||
| NCT03166787 Details | 2021-04-09 Interventional | 1 | 60 | Carbon Monoxide Charcoal Tadalafil Endothelial Dys… Smoking | Due to the Pandemic and the nature of this study we decided to terminate this study. - | |||
| NCT02685267 Details | 2021-04-09 Interventional | 2 | 9 | Docetaxel Prednisone Prostatic Neopl… Prostate Cancer | - - | |||
| NCT04666675 Details | 2021-04-08 Interventional | 3 | 0 | Upadacitinib Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | Strategic considerations - | |||
| NCT04626089 Details | 2021-04-08 Interventional | 2 | [44 Refs] | 0 | Metformin Diabetes Mellit… Metabolic Syndr… Severe Acute Re… Syndrome Severe Acute Re… Type 2 Diabetes | Administrative decision of the company - | ||
| NCT03510455 Details | 2021-04-08 Interventional | 2 | 4 | Infigratinib Neoplasms, Conn… Osteomalacia Oncogenic Osteo… Tumor-Induced O… | Study was stopped early due to a greater than expected incidence of ocular AEs and analysis of
the data from the first 4 subjects indicating that the likelihood of permanent remission with
this therapy was low. This study was terminated early due to a lack of efficacy in the first 4 patients and an unexpectedly high rate of ocular adverse events. As a result, only 4 patients were enrolled in this study. Because of the small sample size, we were unable to perform the planned statistical analysis, and instead the results are primarily descriptive. | |||
| NCT02336048 2014-004594-16 Details | 2021-04-08 Interventional | 1 | 38 | Chlorambucil Obinutuzumab Leukemia Leukemia, Lymph… Leukemia, Lymph… B-Cell Chronic … | This study was terminated early because premedication with tocilizumab was unlikely to reduce
the risk of IRR. - | |||
| NCT02036502 2013-003512-44 Details | 2021-04-08 Interventional | 1 | [1 Refs] | 77 | Dexamethasone Lenalidomide Pembrolizumab Multiple Myelom… Neoplasms, Plas… | Business Reasons Enrollment of participants into this study was stopped after the FDA implemented a clinical hold after determining the risks of pembrolizumab + pomalidomide or lenalidomide outweighed any potential benefit for participants with multiple myeloma. | ||
| NCT01573338 2011-004155-39 Details | 2021-04-08 Interventional | 1/2 | 43 | Carboplatin Etoposide Lung Neoplasms Small Cell Lung… | - - | |||
| NCT02805660 Details | 2021-04-06 Interventional | 1/2 | 83 | Durvalumab Mocetinostat Advanced Cancer | The study was discontinued early because the Sponsor de-prioritized development of
mocetinostat. The decision to stop was not due to any patient safety issues. The study was discontinued early because the Sponsor de-prioritized development of mocetinostat. The decision to stop was not due to any patient safety issues. | |||
| NCT02468557 Details | 2021-04-02 Interventional | 1 | 16 | Idelalisib Paclitaxel Adenocarcinoma Previously Untr… Relapsed/Refrac… | - Due to the early termination of the study, the prespecified efficacy, pharmacodynamic, and pharmacokinetic analysis for PK parameters were not conducted. | |||
| NCT04341493 Details | 2021-04-01 Interventional | 4 | 44 | Hydroxychloroqu… Nitazoxanide Coronavirus Inf… Coronavirus Inf… | Concerns about safety of Hydroxychloroquine - | |||
| NCT02025218 Details | 2021-04-01 Interventional | 2 | 21 | Gefitinib Lung Neoplasms Lung Cancer | - - | |||
| NCT00570258 Details | 2021-03-30 Interventional | 2 | 27 | Erlotinib Hydro… Fulvestrant Breast Neoplasm… Metastatic Brea… | FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment
stopped, those on treatment were given option to opt out. Early termination due to a change in drug FDA approval. Outcome measures not computed because data would not be statistically relevant. |